InvestorsHub Logo
icon url

IPRE-Paramount

01/14/11 7:49 PM

#10419 RE: saigai #10418

IBIO 4.9,it's quite late. When i look at the chart what we missed is depressing . BUT the small cap publisher PRESS said that this company is owning new technology that will accelerate some BIOtech R&D !!

Also IBIO is just new listed on AMEX since 10 day ! from otcbb!! That's why the stock was a MONSTER GEM rallying from pennies to $5 .



Goldman Small Cap Research Initiates Coverage of iBio, Inc.
WEDNESDAY, JANUARY 05, 2011 10:30 AM
- GlobeNewswire




IBIO
4.91 +1.01





Enter Symbol:



Enter Keyword:



BALTIMORE, Jan 5, 2011 (GlobeNewswire via COMTEX) -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has initiated research coverage of iBio, Inc. (IBIO) , an emerging biotechnology company that has developed a unique alternative platform that could help revolutionize the mass production of key vaccines and biosimilars.

In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines the reasoning behind the coverage initiation.

"iBio's paradigm-changing platform takes the old model biotech and changes it such that revenue generation could be faster, along with lower capital costs. In our view, validation has already occurred with its relationships with and funding from DARPA and the Gates Foundation."

To view a summary of the report or download the report in its entirety, please visit http://goldmanresearch.com/index.php/new-reports.html

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap stock market research reports and weekly newsletters. For more information, visit www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer. To download our research, disclosures, or for more information, visit www.goldmanresearch.com.

About IBio, Inc.: iBio, Inc. (IBIO) a biotechnology company offering its proprietary, transformative iBioLaunch technology platform for the production of biologics including therapeutic proteins -- orphan biologics, biosimilars and biobetters -- and vaccines. The iBioLaunch platform uses transient gene expression in green plants for superior efficiency in protein production. The iBioLaunch technology was developed by the not-for-profit Fraunhofer USA Center for Molecular Biotechnology (FCMB) during the past eight years to overcome the inadequacies of existing technologies. iBio owns the intellectual property and technology developed at FCMB, and continues to sponsor development and application of the technology for biological applications in human health.

For more information and disclosures, visit www.ibioinc.com.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Goldman Small Cap Research

CONTACT: Goldman Small Cap Research
Rob Goldman, Analyst
410-609-7100
rob@goldmanresearch.com


(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved
icon url

iamcanadian

01/14/11 8:12 PM

#10420 RE: saigai #10418

I'm in the same boat - bought a book, tried a demo account on options with Think or Swim - best I can make out, options are like canadian stock warrants, except eith options, targets can be long or short - I believe
icon url

saigai

01/15/11 3:22 AM

#10423 RE: saigai #10418

hey can you put biod and xpgh in the ibox

xpgh and the bio diesel tax credit plus a landmark legal victory plus the solar hot water systems they are selling makes this a buy and hold...easy money

from yahoo

The biodiesel industry got another early Christmas present when a district appeals court today denied a petition challenging the Renewable Fuels Standard (RFS2).

The U.S. District Court of Appeals for the District of Columbia set forth a unanimous decision to deny the petition by National Petrochemical Refiners Association (NPRA) and the American Petroleum Institute (API) challenging the Renewable Fuels Standard (RFS2). The petition was filed in March of this year saying the RFS2 violated the statutory requirements setting separate biomass-based diesel volume requirements for 2009 and 2010, that it was inappropriately retroactive without proper lead time and compliance provisions.
The National Biodiesel Board’s (NBB) was obviously pleased to hear about the decision. “This wholly validates the U.S. biodiesel industry’s legal position and sends a clear, unambiguous signal to the marketplace that the common-sense renewable goals established in the RFS2 program will be met,” said Manning Feraci, NBB Vice President of Federal Affairs.

Renewable Energy Group (REG), the nation’s largest biodiesel producer, also applauded the decision.
“This lawsuit was the final piece of uncertainty creating market disruption for the biodiesel industry. With last week’s reinstatement of the biodiesel blenders’ tax credit and today’s announcement by the court, REG is bullish on the 2011 market for biodiesel demand,” said REG’s Gary Haer, who is the new president of NBB.
More than 1.4 billion gallons of biodiesel production is registered with the EPA to produce valid RINs to meet required volume obligations. Renewable Energy Group has more than 180 million gallons of production capacity. The company anticipates significant demand increases in coming weeks due to these recent announcements.
Meanwhile, NPRA “expressed disappointment and concern” over the decision. “This retroactive regulation by a federal agency establishes a deeply troubling and potentially far-reaching precedent,” said NPRA president Charles Drevna. “We’re disappointed that the court did not overturn what is clearly a flawed and misguided approach toward implementation of the federal Renewable Fuels Standard. Regardless of the court’s ruling, however, NPRA and its members remain committed to working towards the overall implementation of the RFS program.”
Even though the thrust of the challenge was related to biodiesel, Growth Energy had intervened in the court case on behalf of the ethanol industry to help defend the mandated volumes and make sure that the volumetric levels were retroactive as of Jan 2010. “We intervened because we believe that EPA’s decision regarding the mandated volume of domestic renewable fuels furthers the intent of Congress,” Growth Energy said in a statement


Sentiment : Strong Buy
icon url

IHUBfan

01/15/11 12:58 PM

#10432 RE: saigai #10418

Geo, you are better off sticking with what is working for you.
You can lose a lot of money with options, which is what happened to me. But it is very addictive.
But you can always learn and use them with extreme care and benefit form them.
If you google options you will get a lot of sites.
But here is the one I like:
http://www.optionseducation.org/